The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Abstract
Background Optimum management strategies for patients with advanced non-small-cell lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are undefined. We aimed to assess the efficacy and safety of continuing gefitinib combined with chemotherapy versus chemotherapy alone in patients with EGFR-mutation-positive advanced NSCLC with acquired resistance to first-line gefitinib.Methods The randomised, phase 3, multicentre IMPRESS study was done in 71 centres in 11 countries in Europe and the Asia-Pacific region. Eligible patients were aged at least 18 years with histologically confirmed, chemotherapy-naive, stage IIIB-IV EGFR-mutation-positive advanced NSCLC with previous disease control with first-line gefitinib and recent disease progression (Response Evaluation Criteria in Solid Tumors version 1.1). Participants were randomly assigned (1:1) by central block randomisation to oral gefitinib 250 mg or placebo once daily in tablet form; randomisation did not include stratification factors. All patients also received the platinum-based doublet chemotherapy cisplatin 75 mg/m(2) plus pemetrexed 500 mg/m(2) on the first day of each cycle. After completion of a maximum of six chemotherapy cycles, patients continued their randomly assigned treatment until disease progression or another discontinuation criterion was met. All study investigators and participants were masked to treatment allocation. The primary endpoint was progression-free survival in the intention-to-treat population. Safety was assessed in patients who received at least one dose of study treatment. The study has completed enrolment, but patients are still in follow-up for overall survival. This trial is registered with ClinicalTrials.gov, number NCT01544179.Findings Between March 29, 2012, and Dec 20, 2013, 265 patients were randomly assigned: 133 to the gefitinib group and 132 to the placebo group. At the time of data cutoff (May 5, 2014), 98 (74%) patients had disease progression in the gefitinib group compared with 107 (81%) in the placebo group (hazard ratio 0·86, 95% CI 0·65-1·13; p=0·27; median progression-free survival 5·4 months in both groups [95% CI 4·5-5·7 in the gefitinib group and 4·6-5·5 in the placebo group]). The most common adverse events of any grade were nausea (85 [64%] of 132 patients in the gefitinib group and 81 [61%] of 132 patients in the placebo group) and decreased appetite (65 [49%] and 45 [34%]). The most common adverse events of grade 3 or worse were anaemia (11 [8%] of 132 patients in the gefitinib group and five [4%] of 132 patients in the placebo group) and neutropenia (nine [7%] and seven [5%]). 37 (28%) of 132 patients in the gefitinib group and 28 (21%) of 132 patients in the placebo group reported serious adverse events.Interpretation Continuation of gefitinib after radiological disease progression on first-line gefitinib did not prolong progression-free survival in patients who received platinum-based doublet chemotherapy as subsequent line of treatment. Platinum-based doublet chemotherapy remains the standard of care in this setting.Funding AstraZeneca.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“No difference in response rates (32% versus 34%) or median PFS (5.4 months in both groups) was demonstrated.”
In the citing paper
“However, a subsequent subgroup analysis stratifying patients according to plasma T790M status at time of progression suggested a role for continuing gefitinib in those who are T790M negative.”
In the citing paper
“At the present time, when rebiopsy is not feasible or when the EGFR T790M mutation is not detected as a resistance mechanism, the standard of care is represented by platinum-based chemotherapy alone.There is no data to support continuation of the EGFR TKI with platinum-based chemotherapy [I, A] [125].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [125]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citationGefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citationMitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Self-citationZhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Self-citationPao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citation
Cited by
Sorted by citations
Items 401–411 of 411
Liu, T. F. D., Kazmi, F., Barry, C., Mishra, S. R., Dahal, P. K., Katyal, R., & Shrestha, N. (2025) · Research Square · doi:10.21203/rs.3.rs-7091849/v1
Niu, J., Zhu, H., Shi, Z., Sun, Z., Jing, X., & Zd, L. (2026) · Scientific Reports · doi:10.1038/s41598-026-54690-y
Shao, W., Gu, W., Song, S., Chen, D., Shao, Z.-M., Sun, Q., & Yu, H. (2026) · BMC Cancer · doi:10.1186/s12885-026-15957-9
“These sensitizing mutations confer significant clinical benefit from EGFR tyrosine kinase inhibitors (TKIs), prolonging survival by 9 to 13 months compared with conventional chemotherapy [5, 6].”
Liu, P., Chen, Y., Chen, W.-L., Ho, C., & Lee, C.-H. (2026) · Current Oncology · doi:10.3390/curroncol33060311
“The efficacy of chemotherapy in this context is underscored by historical benchmarks from the IMPRESS [24] and KCSG-LU12-13 trials [25], in which platinum-pemetrexed combinations after TKI progression yielded median PFS rates of 4.2 to 5.6 months.”
InfluentialZhang, L., Huang, L., Huang, D., Liu, Z., Yu, Y. P., Miao, K., Miao, Q., Zheng, X., Xu, Y., Chu, Q., et al. (2026) · MedComm · doi:10.1002/mco2.70855
“Combination regimens combining EGFR-TKIs and chemotherapy have proven highly effective in multiple settings [ 38–40 ].”
Target-specific cardiotoxicity of tyrosine kinase inhibitors: a Systematic Review and meta-analysis
Wang, Z., Cheng, Z., Zheng, Y., Liu, Y., Zhang, Z., Gao, Y., & Li, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1807099
“…et al., 2013; Cicènas et al., 2016; Brose et al., 2024; Middleton et al., 2017; Gupta et al., 2016; Sanborn et al., 2017; Argiris et al., 2013; Soria et al., 2015; Dutton et al., 2014; Cristofanilli et al., 2010; Brose et al., 2021; Brose et al., 2022; Matsubara et al., 2024; Yang et al.,…”
Ren, J., Huang, Y., Li, L., Jin, Y., & Yin, Y. (2026) · Cancer Imaging · doi:10.1186/s40644-026-01122-9
“…as follows: [1] Patients diagnosed with lung adenocarcinoma by surgical resection or biopsy; [2] PCCT was performed within 2 weeks before surgery or biopsy, with diagnostic-quality images available for all patients; [3] Age ≥ 18 years; [4] Complete clinical and pathological data were available.”
Goldman, J. W., Riess, J. W., Cho, B. C., Goldberg, S. B., Le, X., Piotrowska, Z., Okamoto, I., Yu, H. A., Campelo, M. R. G., de Castro, J., et al. (2026) · Clinical Lung Cancer · doi:10.1016/j.cllc.2026.09.001
Self-citationChen, Y., Chen, S., Zhang, H., Xie, J., Song, B., & Xu, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1909040
Hong, S., Zhou, T., Hou, X., Meng, X., Hu, Z., Zheng, W., Cui, J., Luo, Y., Wu, L., Huang, M., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)02026-x
Metadata
- Authors
- Soria, J.-C., Wu, Y.-L., Nakagawa, K., Kim, S.-W., Yang, J.-J., Ahn, M.-J., Wang, J., Yang, J. C.-H., Lu, Y., Atagi, S., Ponce, S., Lee, D. H., Liu, Y., Yoh, K., Zhou, J.-Y., Shi, X., Webster, A., Jiang, H., & Mok, T. S. K.
- Affiliations
- Institut Gustave Roussy (FR)
- Guangdong General Hospital (CN)
- Kindai University (JP)
- Asan Medical Center (KR)
- National Taiwan University (TW)
- Samsung Medical Center (KR)
- Peking University Cancer Hospital (CN)
- NHO Kinki Chuo Chest Medical Center (JP)
- Hospital Universitario 12 De Octubre (ES)
- First Hospital of China Medical University (CN)
- National Cancer Center Hospital East (JP)
- AstraZeneca (United Kingdom) (GB)
- Chinese University of Hong Kong (HK)
- Corresponding author
- Mok, Tony S K
- ORCID
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 16
- Issue
- 8
- Pages
- 990-998
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W2152481222
- Semantic Scholar
- 8a3893572a340f3e2e3dc31440e3947d55eb0893
- Cited by
- 413
- References
- 30
- Citations by year
- 2026: 13 · 2025: 22 · 2024: 21 · 2023: 28 · 2022: 28 · 2021: 34 · 2020: 36 · 2019: 35 · 2018: 53 · 2017: 66 · 2016: 61 · 2015: 15
- FWCI
- 51.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- gefitinib, EGFR mutation, non-small cell lung cancer, acquired resistance, EGFR tyrosine kinase inhibitors, cisplatin, pemetrexed, platinum-based chemotherapy, progression-free survival, second-line therapy, treatment safety, overall survival, quality of life, patient-reported outcomes, adverse events
- MeSH terms
- Pemetrexed, Gefitinib, Administration, Oral, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Asia, Carcinoma, Non-Small-Cell Lung, Cisplatin, Drug Administration Schedule, Europe, Female, Glutamates, Guanine, Humans, Infusions, Intravenous, Lung Neoplasms, Male, Middle Aged, Mutation, Phenotype, Prospective Studies, Quinazolines, Time Factors, Biomarkers, Tumor, Proportional Hazards Models, Treatment Outcome, Disease Progression, Disease-Free Survival, Genetic Predisposition to Disease, Protein Kinase Inhibitors, Kaplan-Meier Estimate, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
